Cargando…

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study

BACKGROUND: Impaired coronary microcirculation is associated with a poor prognosis in patients with type 2 diabetes. In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary microcirculation. Studies have shown beneficial effects of glucagon-like peptide-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faber, Rebekka, Zander, Mette, Pena, Adam, Michelsen, Marie M, Mygind, Naja D, Prescott, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407869/ https://www.ncbi.nlm.nih.gov/pubmed/25896352 http://dx.doi.org/10.1186/s12933-015-0206-3

Ejemplares similares

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study
por: Mygind, Naja Dam, et al.
Publicado: (2016)

Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study
por: Mygind, Naja Dam, et al.
Publicado: (2016)

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
por: Lambadiari, Vaia, et al.
Publicado: (2018)

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction
por: Schroder, Jakob, et al.
Publicado: (2019)

Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria
por: DellaValle, Brian, et al.
Publicado: (2016)

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
por: Kumarathurai, Preman, et al.
Publicado: (2016)

Inflammation, non-endothelial dependent coronary microvascular function and diastolic function—Are they linked?
por: Suhrs, Hannah E., et al.
Publicado: (2020)

Erratum to: Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria
por: DellaValle, Brian, et al.
Publicado: (2016)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis
por: Kapodistria, Katerina, et al.
Publicado: (2018)

The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome
por: Liu, Shenhai, et al.
Publicado: (2020)

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
por: Courrèges, J-P, et al.
Publicado: (2008)

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
por: Liu, Que, et al.
Publicado: (2010)

Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus–A randomized, placebo-controlled cross-over study
por: Suhrs, Hannah Elena, et al.
Publicado: (2022)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Overlap between angina without obstructive coronary artery disease and left ventricular diastolic dysfunction with preserved ejection fraction
por: Michelsen, Marie Mide, et al.
Publicado: (2019)

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
por: Aung, Myo Myo, et al.
Publicado: (2019)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
por: Frøssing, Signe, et al.
Publicado: (2017)

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide
por: Zhao, Xiaoning, et al.
Publicado: (2012)

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
por: Adams, Jessica M., et al.
Publicado: (2018)

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
por: Liljedahl, Leena, et al.
Publicado: (2019)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
por: Shimoda, M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway
por: Liu, Jieyu, et al.
Publicado: (2013)

Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
por: Lu, Nan, et al.
Publicado: (2015)

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats
por: Cheng, Kai-Chun, et al.
Publicado: (2020)

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
por: Inoue, Kazuho, et al.
Publicado: (2022)

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
por: Garber, A, et al.
Publicado: (2011)

Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury
por: Hakon, Jakob, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_na3qultrjfcgieel5480c3i0sn